hrp0084p2-500 | Perinatal | ESPE2015

Birth Incidence of Prader-Willi Syndrome in France

Bar Celine , Diene Gwenaelle , Molinas Catherine , Casper Charlotte , Tauber Maithe

Background: Prader-Willi syndrome (PWS) is a rare and complex genetic disorder characterised in neonates by hypotonia and feeding problems. French birth incidence has never been reported.Objective and hypotheses: To evaluate incidence of PWS at birth in France.Method: Identification of patients with a molecular diagnosis of PWS born between January 1st, 2013 and December 31st, 2013 was obtained by combining va...

hrp0089p1-p190 | Multisystem Endocrine Disorders P1 | ESPE2018

Overview of Leading Causes of Death among French Patients with Prader-Willi Syndrome, 2004–2014

Liz Pacoricona Alfaro Dibia , Lemoine Perrine , Molinas Catherine , Diene Gwenaelle , Arnaud Catherine , Tauber Maithe

Introduction: Prader-Willi Syndrome (PWS) is a complex neurodevelopmental genetic disease comprising multiples cognitive, behavioural and endocrine abnormalities. This rare syndrome is one of the most common known reasons of syndromic obesity, a major cause of morbimortality among this population. In the last 20 years, substantial improvements have been made regarding the diagnosis, treatment and management of patients with PWS. Along those progresses, national policies were d...

hrp0094p2-352 | Pituitary, neuroendocrinology and puberty | ESPE2021

Patients with PWS and related syndromes display differentially methylated regions involved in neurodevelopmental and nutritional trajectory.

Salles Juliette , Franchitto Nicolas , Bieth Eric , Eddiry Sanaa , Molinas Catherine , Salles Jean Pierre , Tauber Maithe ,

Background: Prader-Willi syndrome is a rare genetic neurodevelopmental disorder caused by a paternal deficiency of maternally imprinted gene expression located in the chromosome 15q11-q13 region. Previous studies have demonstrated that several classes of neurodevelopmental disorders can be attributed to either over- or under-expression of specific genes that may lead to impairments in neuronal generation, differentiation, maturation and growth. Epigenetic chan...

hrp0097p1-446 | Fat, Metabolism and Obesity | ESPE2023

The evolution of diagnosis and care over time in children with Prader-Willi syndrome, born between 2005 and 2021, included in the French database.

Faye Sandy , Molinas Catherine , Brochado Cathy , Valette Marion , Desprez Clémence , Diene Gwenaelle , Arnaud Catherine , Tauber Maithé

Introduction: The French Reference Centre PRADORT set up a national Access® database in 2005 for children diagnosed with Prader-Willi Syndrome (PWS). The medical, socio-demographic and family data of 813 patients were then collected.Method: We aim to analyse the evolution of diagnosis and care over time, according to the birth year of patients by comparing 3 groups (patients born between 2005 to 2009, 2010 to 2014 an...

hrp0098p1-65 | Growth and Syndromes 1 | ESPE2024

Cardiovascular autonomic dysfunction and sleep abnormalities in children with Prader-Willi syndrome

Debs Rachel , Diene Gwenaëlle , Cortadellas Julie , Molinas Catherine , Kermorgant Marc , Tauber Maïthé , Pavy Le Traon Anne

Purpose: Prader-Willi syndrome is a rare genetic neurodevelopmental condition characterized by cognitive disabilities, behavioural problems, hypothalamic dysfunction with obesity and sleep disorders. A few studies have reported autonomic nervous system dysfunction. Our aim was to investigate in details dysautonomia combining sleep studies and standard autonomic testing in children with Prader-Willi syndrome regularly followed.Met...

hrp0082p1-d3-125 | Fat Metabolism & Obesity (2) | ESPE2014

Impairment of Adipose Tissue in Prader–Willi Syndrome Rescued by GH Treatment

Cadoudal Thomas , Diene Gwenaelle , Sengenes Coralie , Molinas Catherine , Desneulin Flavie , Eddiry Sanaa , Conte Auriol Francoise , Daviaud Daniele , Bouloumie Anne , Pierre Salles Jean , Valet Philippe , Tauber Maithe

Background: Prader–Willi syndrome (PWS) results from abnormalities in the genomic imprinting process leading to hypothalamic dysfunction with an alteration of GH secretion. PWS is associated with early morbid obesity and short stature which can be efficiently improved with GH treatment.Objective and hypotheses: Our aims were to highlight adipose tissue structural and functional impairments in young children with PWS and to study the effect of GH tre...

hrp0098p1-46 | Fat, Metabolism and Obesity 1 | ESPE2024

Circulating levels of ghrelin in patients with a rare disease with intellectual disability associated with hyperphagia, and/or overweight, and/or obesity – The HOGRID study

Brochado Cathy , Clerc Alice , Benvegnu Grégoire , Diene Gwenaëlle , Jouret Béatrice , Montastier Emilie , Grunenwald Solange , Molinas Catherine , Faye Sandy , Valette Marion , Tauber Maïthé

Introduction: The prevalence of overweight and/or obesity is approximately 2 times higher in people with intellectual disability (ID). Prader-Willi syndrome (PWS) is a rare neurodevelopmental disorder linked to hypothalamic dysfunction. People with PWS display ID and a characteristic nutritional trajectory ranging from anorexia to hyperphagia, leading to early severe obesity. Other rare diseases with ID are associated with eating disorders and overweight. Toda...

hrp0082p1-d3-128 | Fat Metabolism & Obesity (2) | ESPE2014

Acylated and Unacylated Ghrelin Levels in Children and Young Adults with Prader–Willi Syndrome

Kuppens Renske , Diene Gwenaelle , Bakker Nienke , Molinas Catherine , Faye S , Nicolino Marc , Bernoux Delphine , Delhanty Patric , Jan van der Lelij Aart , Allas Soraya , Julien Michiel , Delale Thomas , Tauber Maithe , Hokken-Koelega Anita

Background: Prader–Willi syndrome (PWS) is characterized by a switch in early childhood from failure to thrive to excessive weight gain and hyperphagia with impaired satiety. The underlying mechanism for this switch may involve hyperghrelinemia, but only poor data exists regarding levels of acylated ghrelin (AG), unacylated ghrelin (UAG), and the AG/UAG ratio in PWS.Objective and hypotheses: To investigate plasma levels of AG and UAG in PWS, compare...

hrp0097t10 | Section | ESPE2023

Long term effects at 3-4 years of age of early intranasal oxytocin treatment in infants with Prader-Willi syndrome

Valette Marion , Diene Gwenaelle , Glattard Mélanie , Cortadellas Julie , Molinas Catherine , Faye Sandy , Benvegnu Grégoire , Boulanouar Kader , Payoux Pierre , Pierre SALLES Jean , Arnaud Catherine , Cabal-Berthoumieu Sophie , Tauber Maithé

Introduction: The neuropeptide oxytocin (OT) plays an important role in modulating behaviour and social interactions. Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder due to abnormal hypothalamic development including OT dysfunction that involves endocrine, nutritional and behavioural outcomes/features/trajectory. We previously showed in a phase I/II study (NCT02205034) that 18 infants with PWS, less than 6 months of age, who received ...